Cargando…

A Review of Papillary Renal Cell Carcinoma and MET Inhibitors

Papillary renal cell carcinoma (PRCC) is a subtype of renal cell carcinoma (RCC) accounting for approximately 15–20% of cases and further divided into Type 1 and Type 2. Type 1 PRCC tends to have more alterations in the MET tyrosine kinase receptor than Type 2 PRCC. Treatment for RCC patients is ba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rhoades Smith, Katherine Emilie, Bilen, Mehmet Asim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918905/ https://www.ncbi.nlm.nih.gov/pubmed/31867475 http://dx.doi.org/10.3233/KCA-190058

Ejemplares similares

Ramucirumab and Docetaxel in Patients with Metastatic Urothelial Carcinoma Harboring Fibroblast Growth Factor Receptor Alterations: A Case Series and Literature Review
por: Smith, Katherine Emilie Rhoades, et al.
Publicado: (2020)

Management of metastatic renal cell carcinoma: The complexity of choice
por: Brown, Jacqueline T., et al.
Publicado: (2019)

Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials
por: Zhuang, Tony Zibo, et al.
Publicado: (2022)

Editorial: Case reports in renal cell carcinoma
por: Zhuang, Tony Z., et al.
Publicado: (2023)

The Pathogenetic Role of the HGF/c-Met System in Papillary Carcinoma of the Thyroid
por: Ruco, Luigi, et al.
Publicado: (2014)

Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2019)

An Update on the Treatment of Papillary Renal Cell Carcinoma
por: Chawla, Neal S., et al.
Publicado: (2023)

Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients
por: Yin, Xiaolu, et al.
Publicado: (2015)

iPSC-Derived Embryoid Bodies as Models of c-Met-Mutated Hereditary Papillary Renal Cell Carcinoma
por: Hwang, Jin Wook, et al.
Publicado: (2019)

Case of Hereditary Papillary Renal Cell Carcinoma Type I in a Patient With a Germline MET Mutation in Russia
por: Mikhaylenko, Dmitry S., et al.
Publicado: (2020)

Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report
por: Olsen, T. Anders, et al.
Publicado: (2021)

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review
por: Rochigneux, Philippe, et al.
Publicado: (2018)

Papillary carcinoma of the thyroid: methylation is not involved in the regulation of MET expression
por: Scarpino, S, et al.
Publicado: (2004)

c-Met expression in renal cell carcinoma with bone metastases
por: Silva Paiva, Rita, et al.
Publicado: (2020)

MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors
por: Shuch, Brian, et al.
Publicado: (2015)

Anti‐tumor efficacy of human anti‐c‐met CAR‐T cells against papillary renal cell carcinoma in an orthotopic model
por: Mori, Jun‐ich, et al.
Publicado: (2021)

MET Expression in Sporadic Renal Cell Carcinomas
por: Choi, Jong Sun, et al.
Publicado: (2006)

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
por: Brown, Jacqueline T, et al.
Publicado: (2021)

Characteristics of Clear Cell Papillary Renal Cell Carcinoma (ccpRCC)
por: Rysz, Jacek, et al.
Publicado: (2021)

MET Inhibition in Clear Cell Renal Cell Carcinoma
por: Xie, Zuoquan, et al.
Publicado: (2016)

Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Zhuang, Tony Z, et al.
Publicado: (2022)

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial
por: Choueiri, Toni K., et al.
Publicado: (2020)

Clear cell and papillary renal cell carcinomas in hereditary papillary renal cell carcinoma (HPRCC) syndrome: a case report
por: Ferlicot, Sophie, et al.
Publicado: (2021)

Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma
por: Jansen, Caroline S., et al.
Publicado: (2023)

Metastatic Prostate Cancer Manifesting as Cholestatic Jaundice: A Case Report and Review of the Literature
por: Ravindranathan, Deepak, et al.
Publicado: (2018)

Case of hereditary papillary renal cell carcinoma
por: Mustafa, Sadaf, et al.
Publicado: (2012)

Prognostic models in papillary renal cell carcinoma
por: Attalla, Kyrollis, et al.
Publicado: (2020)

Therapeutic Vaccines for Genitourinary Malignancies
por: Dutcher, Giselle M. A., et al.
Publicado: (2018)

Association Analysis of MET Gene Polymorphism with Papillary Thyroid Carcinoma in a Chinese Population
por: Ning, Lifeng, et al.
Publicado: (2015)

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations
por: Santarpia, Mariacarmela, et al.
Publicado: (2021)

Transitional Cell Carcinoma of the Renal Pelvis With Synchronous Ipsilateral Papillary Renal Cell Carcinoma: Case Report and Review
por: Mucciardi, Giuseppe, et al.
Publicado: (2015)

Inflammatory Markers in Cancer Immunotherapy
por: Ravindranathan, Deepak, et al.
Publicado: (2021)

Clear cell papillary renal cell carcinoma: a case report and literature review
por: Patel, Simmi, et al.
Publicado: (2019)

Clear cell papillary renal cell carcinoma: A case report and review of the literature
por: Kim, Sung Han, et al.
Publicado: (2018)

Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma
por: Martini, Dylan J., et al.
Publicado: (2021)

The Morphological Spectrum of Papillary Renal Cell Carcinoma and Prevalence of Provisional/Emerging Renal Tumor Entities with Papillary Growth
por: Lobo, João, et al.
Publicado: (2021)

Bilateral Native Kidney Papillary Renal Cell Carcinomas in a 11-Year-Old Renal Transplant Patient
por: Durakbaşa, Çiğdem Ulukaya, et al.
Publicado: (2022)

Leptomeningeal carcinomatosis associated with papillary renal cell carcinoma
por: Chilkulwar, Abhishek, et al.
Publicado: (2014)

Characterizing the outcomes of metastatic papillary renal cell carcinoma
por: Connor Wells, John, et al.
Publicado: (2017)

VENUSS rising for papillary renal cell carcinoma prognostication?
por: Buchler, Tomas
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fdut0rhhitt8g7qlv41bou30pg